Nabilone

Drug Profile

Nabilone

Alternative Names: Cesamet

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Developer Valeant Pharmaceuticals International
  • Class Antiemetics; Cannabinoids; Non-opioid analgesics; Small molecules
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Nausea and vomiting
  • Discontinued Fibromyalgia; Insomnia; Muscle spasticity; Neuropathic pain

Most Recent Events

  • 01 Apr 2009 Nabilon is still in clinical development for Neuropathic pain in Canada
  • 01 Apr 2009 No development reported - Phase-II for Insomnia in Canada (PO)
  • 01 Apr 2009 No development reported - Preclinical for Fibromyalgia in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top